IL-1 receptor antagonist treatment aggravates staphylococcal septic arthritis and sepsis in mice

PLoS ONE

Volumn 10, Issue 7, 2015, Pages

  Ali, Abukar ^a   Na, Manli ^a   Svensson, Mattias N D ^a,b   Magnusson, Malin ^a   Welin, Amanda ^a   Schwarze, Jan Christoph ^a   Mohammad, Majd ^a   Josefsson, Elisabet ^a   Pullerits, Rille ^a   Jin, Tao ^a  

^a UNIVERSITY OF GOTHENBURG   (Sweden)

^b LA JOLLA INSTITUTE FOR ALLERGY AND IMMUNOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; CYTOKINE; IL1RN PROTEIN, MOUSE; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL ARTHRITIS; BACTERIAL CLEARANCE; BACTERIAL STRAIN; BONE DESTRUCTION; CONTROLLED STUDY; DISEASE COURSE; DISEASE EXACERBATION; FEMALE; HISTOPATHOLOGY; INFECTION SENSITIVITY; MORTALITY; MOUSE; NONHUMAN; POLYARTHRITIS; STAPHYLOCOCCAL BACTEREMIA; ANIMAL; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, INFECTIOUS; DISEASE MODEL; INFLAMMATION; JOINT; KIDNEY; METABOLISM; MICRO-COMPUTED TOMOGRAPHY; MICROBIOLOGY; PATHOLOGY; PERITONEUM MACROPHAGE; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS;

MUS; STAPHYLOCOCCUS AUREUS;

ANIMALS; ARTHRITIS, EXPERIMENTAL; ARTHRITIS, INFECTIOUS; CYTOKINES; DISEASE MODELS, ANIMAL; FEMALE; INFLAMMATION; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; JOINTS; KIDNEY; MACROPHAGES, PERITONEAL; MICE; SEPSIS; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS; STAPHYLOCOCCUS AUREUS; X-RAY MICROTOMOGRAPHY;

EID: 84940062180     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0131645     Document Type: Article

References (37)

1. Cao Y, Jiao Y, Wang L, Huang Y, Postlethwaite A, Stuart J, et al. Anakinra as an interleukin 1 receptor antagonist, complicated genetics and molecular impacts - from the point of view of mouse genomics. Int Immunopharmacol. 2012; 13(1):28-36. Epub 2012/03/20. doi: S1567-5769(12)00066-5 [pii] doi: 10.1016/j.intimp.2012.02.014 PMID: 22425556; PubMed Central PMCID: PMC4142626.
2. Jesus AA, Goldbach-Mansky R. IL-1 blockade in autoinflammatory syndromes. Annu Rev Med. 2014; 65:223-44. Epub 2014/01/16. doi: 10.1146/annurev-med-061512-150641 PMID: 24422572; PubMed Central PMCID: PMC4178953.
3. Aksentijevich I, Masters SL, Ferguson PJ, Dancey P, Frenkel J, van Royen-Kerkhoff A, et al. An autoinflammatory disease with deficiency of the interleukin-1-receptor antagonist. N Engl J Med. 2009; 360 (23):2426-37. Epub 2009/06/06. doi: 360/23/2426 [pii] doi: 10.1056/NEJMoa0807865 PMID: 19494218; PubMed Central PMCID: PMC2876877.
4. Martinon F, Aksentijevich I. New players driving inflammation in monogenic autoinflammatory diseases. Nat Rev Rheumatol. 2015; 11(1):11-20. Epub 2014/09/24. doi: nrrheum.2014.158 [pii] doi: 10.1038/nrrheum.2014.158 PMID: 25247411.
5. Fitzgerald AA, Leclercq SA, Yan A, Homik JE, Dinarello CA. Rapid responses to anakinra in patients with refractory adult-onset Still's disease. Arthritis Rheum. 2005; 52(6):1794-803. Epub 2005/06/04. doi: 10.1002/art.21061 PMID: 15934079.
6. Naumann L, Feist E, Natusch A, Langen S, Krause A, Buttgereit F, et al. IL1-receptor antagonist anakinra provides long-lasting efficacy in the treatment of refractory adult-onset Still's disease. Ann Rheum Dis. 2010; 69(2):466-7. Epub 2010/01/29. doi: 69/2/466 [pii] doi: 10.1136/ard.2009.108068 PMID: 20107032.
7. Neel A, Henry B, Barbarot S, Masseau A, Perrin F, Bernier C, et al. Long-term effectiveness and safety of interleukin-1 receptor antagonist (anakinra) in Schnitzler's syndrome: a French multicenter study. Autoimmun Rev. 2014; 13(10):1035-41. Epub 2014/09/16. doi: S1568-9972(14)00175-X [pii] doi: 10.1016/j.autrev.2014.08.031 PMID: 25220180.
8. Zhou ZY, Chen SL, Shen N, Lu Y. Cytokines and Behcet's disease. Autoimmun Rev. 2012; 11 (10):699-704. Epub 2011/12/27. doi: S1568-9972(11)00306-5 [pii] doi: 10.1016/j.autrev.2011.12.005 PMID: 22197901.
9. Schlesinger N, Alten RE, Bardin T, Schumacher HR, Bloch M, Gimona A, et al. Canakinumab for acute gouty arthritis in patients with limited treatment options: results from two randomised, multicentre, active-controlled, double-blind trials and their initial extensions. Ann Rheum Dis. 2012; 71(11):1839-48. Epub 2012/05/16. doi: annrheumdis-2011-200908 [pii] doi: 10.1136/annrheumdis-2011-200908 PMID: 22586173.
10. Schlesinger N, Mysler E, Lin HY, De Meulemeester M, Rovensky J, Arulmani U, et al. Canakinumab reduces the risk of acute gouty arthritis flares during initiation of allopurinol treatment: results of a double-blind, randomised study. Ann Rheum Dis. 2011; 70(7):1264-71. Epub 2011/05/05. doi: ard.2010.144063 [pii] doi: 10.1136/ard.2010.144063 PMID: 21540198; PubMed Central PMCID: PMC3103669.
11. Ali A, Welin A, Schwarze JC, Svensson MN, Na M, Jarneborn A, et al. CTLA4-Ig but not anti-TNF therapy promotes staphylococcal septic arthritis in mice. J Infect Dis. 2015. Epub 2015/04/04. doi: jiv212 [pii] doi: 10.1093/infdis/jiv212 PMID: 25838268.
12. Dinarello CA. Anti-cytokine therapeutics and infections. Vaccine. 2003; 21 Suppl 2:S24-34. Epub 2003/05/24. doi: S0264410X03001968 [pii]. PMID: 12763679.
13. Hultgren OH, Svensson L, Tarkowski A. Critical role of signaling through IL-1 receptor for development of arthritis and sepsis during Staphylococcus aureus infection. J Immunol. 2002; 168(10):5207-12. Epub 2002/05/08. PMID: 11994477.
14. Salliot C, Dougados M, Gossec L. Risk of serious infections during rituximab, abatacept and anakinra treatments for rheumatoid arthritis: meta-analyses of randomised placebo-controlled trials. Ann Rheum Dis. 2009; 68(1):25-32. Epub 2008/01/22. doi: ard.2007.083188 [pii] doi: 10.1136/ard.2007.083188 PMID: 18203761; PubMed Central PMCID: PMC2596305.
15. Goldenberg DL. Septic arthritis. Lancet. 1998; 351(9097):197-202. Epub 1998/02/05. doi: S0140-6736(97)09522-6 [pii] doi: 10.1016/S0140-6736(97)09522-6 PMID: 9449882.
16. Kaandorp CJ, Krijnen P, Moens HJ, Habbema JD, van Schaardenburg D. The outcome of bacterial arthritis: a prospective community-based study. Arthritis Rheum. 1997; 40(5):884-92. Epub 1997/05/01. doi: 10.1002/1529-0131(199705)40:5<884::AID-ART15>3.0.CO;2-6 PMID: 9153550.
17. Kaandorp CJ, Van Schaardenburg D, Krijnen P, Habbema JD, van de Laar MA. Risk factors for septic arthritis in patients with joint disease. A prospective study. Arthritis Rheum. 1995; 38(12):1819-25. Epub 1995/12/01. PMID: 8849354.
18. Kwiecinski J, Jacobsson G, Karlsson M, Zhu X, Wang W, Bremell T, et al. Staphylokinase Promotes the Establishment of Staphylococcus aureus Skin Infections While Decreasing Disease Severity. J Infect Dis. 2013; 208(6):990-9. Epub 2013/06/27. doi: jit288 [pii] doi: 10.1093/infdis/jit288 PMID: 23801604.
19. Davidsson L, Bjorkman L, Christenson K, Alsterholm M, Movitz C, Thoren FB, et al. A simple skin blister technique for the study of in vivo transmigration of human leukocytes. J Immunol Methods. 2013; 393 (1-2):8-17. Epub 2013/04/11. doi: S0022-1759(13)00105-1 [pii] doi: 10.1016/j.jim.2013.03.013 PMID: 23570945.
20. Kwiecinski J, Rhost S, Lofbom L, Blomqvist M, Mansson JE, Cardell SL, et al. Sulfatide attenuates experimental Staphylococcal aureus sepsis through a CD1d dependent pathway. Infect Immun. 2013. Epub 2013/01/24. doi: IAI.01334-12 [pii] doi: 10.1128/IAI.01334-12 PMID: 23340309.
21. Sgroi A, Gonelle-Gispert C, Morel P, Baertschiger RM, Niclauss N, Mentha G, et al. Interleukin-1 receptor antagonist modulates the early phase of liver regeneration after partial hepatectomy in mice. PLoS One. 2011; 6(9):e25442. Epub 2011/10/08. doi: 10.1371/journal.pone.0025442 PONE-D-11-06748 [pii]. PMID: 21980458; PubMed Central PMCID: PMC3181321.
22. Bremell T, Lange S, Yacoub A, Ryden C, Tarkowski A. Experimental Staphylococcus aureus arthritis in mice. Infect Immun. 1991; 59(8):2615-23. PMID: 1855981.
23. Fei Y, Wang W, Kwiecinski J, Josefsson E, Pullerits R, Jonsson IM, et al. The combination of a tumor necrosis factor inhibitor and antibiotic alleviates staphylococcal arthritis and sepsis in mice. J Infect Dis. 2011; 204(3):348-57. Epub 2011/07/12. doi: jir266 [pii] doi: 10.1093/infdis/jir266 PMID: 21742832.
24. Ali A, Zhu X, Kwiecinski J, Gjertsson I, Lindholm C, Iwakura Y, et al. Antibiotic-Killed Staphylococcus aureus Induces Destructive Arthritis in Mice. Arthritis Rheumatol. 2015; 67(1):107-16. Epub 2014/10/11. doi: 10.1002/art.38902 PMID: 25302691.
25. Franzen CA, Simms PE, Van Huis AF, Foreman KE, Kuo PC, Gupta GN. Characterization of uptake and internalization of exosomes by bladder cancer cells. Biomed Res Int. 2014; 2014:619829. Epub 2014/02/28. doi: 10.1155/2014/619829 PMID: 24575409; PubMed Central PMCID: PMC3915764.
26. Epstein JH, Zimmermann B 3rd, Ho G Jr. Polyarticular septic arthritis. J Rheumatol. 1986; 13(6):1105-7. Epub 1986/12/01. PMID: 3494122.
27. Dubost JJ, Fis I, Denis P, Lopitaux R, Soubrier M, Ristori JM, et al. Polyarticular septic arthritis. Medicine (Baltimore). 1993; 72(5):296-310. Epub 1993/09/01. PMID: 8412643.
28. Garcia-Arias M, Balsa A, Mola EM. Septic arthritis. Best Pract Res Clin Rheumatol. 2011; 25(3):407-21. Epub 2011/11/22. doi: S1521-6942(11)00025-8 [pii] doi: 10.1016/j.berh.2011.02.001 PMID: 22100289.
29. Verdrengh M, Tarkowski A. Role of neutrophils in experimental septicemia and septic arthritis induced by Staphylococcus aureus. Infect Immun. 1997; 65(7):2517-21. PMID: 9199413.
30. Leff JA, Baer JW, Bodman ME, Kirkman JM, Shanley PF, Patton LM, et al. Interleukin-1-induced lung neutrophil accumulation and oxygen metabolite-mediated lung leak in rats. Am J Physiol. 1994; 266(1 Pt 1):L2-8. Epub 1994/01/01. PMID: 8304466.
31. Wankowicz Z, Megyeri P, Issekutz A. Synergy between tumour necrosis factor alpha and interleukin-1 in the induction of polymorphonuclear leukocyte migration during inflammation. J Leukoc Biol. 1988; 43 (4):349-56. Epub 1988/04/01. PMID: 3258346.
32. Ulich TR, Yin SM, Guo KZ, del Castillo J, Eisenberg SP, Thompson RC. The intratracheal administration of endotoxin and cytokines. III. The interleukin-1 (IL-1) receptor antagonist inhibits endotoxin- and IL-1-induced acute inflammation. Am J Pathol. 1991; 138(3):521-4. Epub 1991/03/01. PMID: 1825745; PubMed Central PMCID: PMC1886271.
33. Schultz MJ, Rijneveld AW, Florquin S, Edwards CK, Dinarello CA, van der Poll T. Role of interleukin-1 in the pulmonary immune response during Pseudomonas aeruginosa pneumonia. Am J Physiol Lung Cell Mol Physiol. 2002; 282(2):L285-90. Epub 2002/01/17. doi: 10.1152/ajplung.00461.2000 PMID: 11792633.
34. Cho JS, Guo Y, Ramos RI, Hebroni F, Plaisier SB, Xuan C, et al. Neutrophil-derived IL-1beta is sufficient for abscess formation in immunity against Staphylococcus aureus in mice. PLoS Pathog. 2012; 8 (11):e1003047. Epub 2012/12/05. doi: 10.1371/journal.ppat.1003047 PPATHOGENS-D-12-00822 [pii]. PMID: 23209417; PubMed Central PMCID: PMC3510260.
35. Labrousse D, Perret M, Hayez D, Da Silva S, Badiou C, Couzon F, et al. Kineret(R)/IL-1ra blocks the IL-1/IL-8 inflammatory cascade during recombinant Panton Valentine Leukocidin-triggered pneumonia but not during S. aureus infection. PLoS One. 2014; 9(6):e97546. Epub 2014/06/07. doi: 10.1371/journal.pone.0097546 PONE-D-13-46111 [pii]. PMID: 24905099; PubMed Central PMCID: PMC4048174.
36. Mangan DF, Wahl SM. Differential regulation of human monocyte programmed cell death (apoptosis) by chemotactic factors and pro-inflammatory cytokines. J Immunol. 1991; 147(10):3408-12. Epub 1991/11/15. PMID: 1940344.
37. Laupland KB, Church DL, Mucenski M, Sutherland LR, Davies HD. Population-based study of the epidemiology of and the risk factors for invasive Staphylococcus aureus infections. J Infect Dis. 2003; 187 (9):1452-9. Epub 2003/04/30. doi: JID30038 [pii] doi: 10.1086/374621 PMID: 12717627.